Back to JNJ
JNJ Research: Growth, Valuation and Key Risks
$JNJNEUTRALDrug Manufacturers—General

JNJ Research: Growth, Valuation and Key Risks

Johnson & Johnson reported a recent earnings beat and its shares are near a 52-week high, while analyst ratings remain broadly positive. But the mean target is close to the Friday close, and valuation and legal risks remain important parts of the picture.

November 14, 202612 min read
Current Price
$285.75
+0.79%
Analyst Rating
Strong Buy
Price Target
$285.31
-0.2% upside
P/E Ratio
43.32

Executive Summary

Investment Thesis: Johnson & Johnson combines a large pharmaceutical business with medical technology operations, a diversified product portfolio and a long record of dividend payments. Its latest reported quarter beat the supplied EPS estimate, and the available data show 5.9% revenue growth, but the stock has already gained substantially and sits near its 52-week high. Analyst sentiment is favorable, yet the supplied mean target implies essentially no upside from Friday’s close, leaving valuation and execution central to the outlook.

Current Price: $285.75 as of Friday, November 13 | Key Metric: 43.32 trailing P/E | Stance: NEUTRAL

Company Overview

Johnson & Johnson is a global healthcare company operating in pharmaceuticals and medical technology. Its scale, research capabilities and range of products make it less dependent on any single medicine than a narrowly focused biotechnology company, though individual product patents and clinical results still matter substantially.

Key Products & Competitive Position

  • Core Business: Innovative medicines and medical technology, serving markets that include oncology, immunology, neuroscience, cardiovascular care and surgery.
  • Key Products: The portfolio includes medicines such as Darzalex, Stelara and Tremfya, alongside surgical, cardiovascular and vision-related technologies. Product sales and competitive positions can change as patents expire and treatment standards evolve.
  • Competitive Moat: Global distribution, established relationships with healthcare providers, regulatory expertise and a broad research portfolio support its position. These advantages do not remove the risks of clinical setbacks, pricing pressure or competition from newer therapies.

Recent Developments

The supplied company news is largely general dividend and retirement coverage, not reporting on a new J&J product or corporate event. The latest company-specific data point is the October 13, 2026 earnings report, where EPS of $2.59 beat the $2.52 estimate. The next stated report date is January 26, 2027. Investors will also want to track portfolio growth, patent-related sales pressure and ongoing legal matters, although the supplied material does not quantify their latest financial effects.

Financial Snapshot

Market Cap$687.89B
P/E Ratio43.32
52-Week Range$193.55 - $288.11
Dividend Yield1.85%
EPS (TTM)$6.58
ROE19.55%

Revenue & Earnings Trends

The supplied financial snapshot reports revenue growth of 5.9% and free cash flow of approximately $18.5 billion. The latest earnings report beat its estimate by $0.07 per share, or about 2.8% of the estimate. However, the web data also show an earnings-growth figure of -95.9%. That unusually sharp decline may reflect comparison effects or a particular reporting period, and the supplied information does not explain it, so it shouldn't be treated as a clean measure of the company’s underlying trend. TTM EPS is reported as $6.58 in the profile and $6.59 in the web extract, a small source difference.

Balance Sheet Highlights

The web extract reports $17.2 billion in cash, $44.7 billion in total debt, a current ratio of 1.02 and a quick ratio of 0.65. These figures indicate that cash and short-term assets should be considered alongside substantial obligations, rather than treating the cash balance alone as a measure of balance-sheet strength. Operating cash flow of approximately $26.2 billion and free cash flow of $18.5 billion provide context for the company’s ability to fund operations, investment and dividends. Reported ROE is 19.55% in the supplied metrics and 20.02% in the web extract.

Valuation Analysis

Current Valuation Metrics

Forward P/E24.6Industry comparison not supplied
PEG Ratio3.19Growth-adjusted
EV/EBITDA20.7Historical comparison not supplied
P/S Ratio7.2 EV/revenuePeer comparison not supplied

Historical Comparison

A five-year average valuation wasn't included in the supplied data, so a precise historical premium or discount can't be established here. The current trailing P/E of 43.32 is notably higher than the forward P/E of 24.59, based on the web extract’s forward EPS estimate of $11.62. That gap makes the earnings outlook and the quality of projected earnings important to valuation. The PEG ratio of 3.19 also suggests that the share price is high relative to the growth measure used in that calculation, though PEG inputs can vary by provider.

Fair Value Estimate

The supplied analyst mean target of $285.31 is nearly equal to the Friday close of $285.75, implying about 0.2% downside. A separate Yahoo Finance extract gives a mean target of $279.41, also below the close, and a different low target. These target sets are inconsistent, so they should be treated as reference points rather than a precise fair-value estimate. Without cash-flow forecasts, discount-rate assumptions and a consistent target dataset, this report does not assign an independent DCF value. The available evidence suggests a share price where expectations are substantial and the margin for error deserves attention.

Competitive Landscape

Market Position

Market Share: No single percentage is meaningful across J&J’s different drug and medical technology markets | Ranking: Among the largest diversified global healthcare companies

Key Competitors

Merck & (MRK)Pharmaceutical company competing in areas including oncology and vaccines.
AbbVie (ABBV)Large biopharmaceutical company with significant immunology and oncology operations.
Eli Lilly and (LLY)Pharmaceutical competitor with growing positions in major therapeutic markets.

Competitive Advantages

  • Portfolio breadth: Operations across medicines and medical technology reduce reliance on a single product category, though they don't eliminate product-specific exposure.
  • Scale and reach: Global commercial infrastructure and established healthcare relationships can support product launches and distribution.
  • Research and development: A substantial research platform gives the company opportunities to develop or acquire new products, with outcomes dependent on clinical and regulatory results.

Earnings Track Record

Last 4 Quarters: 1 confirmed beat / 0 confirmed misses, with 3 quarters of supplied results unavailable

Recent Earnings History

Q3 2026$2.59 vs $2.52 estBEAT
Q2 2026Result and estimate not suppliedUNAVAILABLE
Q1 2026Result and estimate not suppliedUNAVAILABLE
Q4 2025Result and estimate not suppliedUNAVAILABLE

Guidance Trend

The supplied information gives an EPS estimate of $2.91 for the January 26, 2027 report, but no company-issued full-year guidance or revision history. Analysts’ estimates can change before a report and aren't equivalent to management guidance. A useful read-through will include whether revenue growth is broad-based, how product mix affects margins and whether management explains the reported year-over-year earnings decline in the web data.

Analyst Sentiment

Consensus Rating: Strong Buy, according to the supplied 23-analyst dataset

Strong Buy: 5Buy: 11Hold: 6Sell: 1Strong Sell: 0

Price Targets

  • Low: $260
  • Mean: $285.31 (-0.2% implied downside)
  • High: $320

Recent Analyst Actions

No individual recent rating changes were provided. The supplied distribution is positive overall, with 16 of 23 analysts in the Strong Buy or Buy categories, but the mean target is essentially at the current share price. The separate web extract reports 22 analyst opinions, a mean target of $279.41 and a low target of $190, rather than $260. Different contributor sets or update timing may account for the discrepancy. The consensus label reflects analysts’ views, not a guarantee of returns or a recommendation in this report.

Recent News & Catalysts

Key Developments

  • Latest reported earnings: J&J reported Q3 2026 EPS of $2.59 against an estimate of $2.52. This is a positive near-term data point, but one quarter alone doesn't establish a sustained earnings trend.
  • Dividend-related coverage: The November 13 headlines discuss healthcare dividend stocks and income planning. They aren't company-specific operating announcements. J&J’s supplied dividend yield is 1.85%, so income comparisons depend on both yield and the durability of future distributions.
  • Shares near the 52-week high: At $285.75, the stock was about 0.8% below its listed high of $288.11 as of Friday. A strong past move can reflect improving expectations, but it also increases the importance of whether business results support the price.

Upcoming Catalysts

Next Earnings: January 26, 2027, expected EPS $2.91 | Key Events: Quarterly sales and margins, management’s outlook, product and pipeline updates, patent exposure and legal developments

US markets were closed on Saturday, November 14. The next regular trading session is Monday, November 16, so the quoted share price and daily change refer to Friday, November 13, not Saturday trading.

Technical Outlook

Current Price: $285.75 vs 52-Week High: $288.11 (-0.8% from high)

Trend Analysis

The price is close to the top of its 52-week range, after a reported 44.7% 52-week change in the web data. The two-year total return in the same extract is 98.61%, although past performance doesn't indicate what comes next. Beta of approximately 0.2 to 0.23 points to comparatively low historical sensitivity to broad market moves, not an absence of company-specific or valuation risk. Is the current strength supported by continuing earnings growth? The next results and management outlook will help answer that question.

Key Levels

  • Resistance: $288.11, the listed 52-week high, then $300 as a round-number reference
  • Support: Approximately $280 to $285 as a near-price reference, then $260, the supplied analyst low target. These are indicative levels, not verified historical support zones.

Bull vs Bear Case

Bull Case

  • Earnings execution: The latest reported EPS beat and 5.9% revenue growth offer evidence of ongoing business momentum.
  • Portfolio and cash generation: A diversified healthcare portfolio and reported $18.5 billion in free cash flow may help support investment and shareholder distributions.
  • Analyst optimism: Most analysts in the supplied panel rate the shares Buy or Strong Buy, and the high target is $320, about 12.0% above Friday’s close.

Bull Target: $320 (+12.0%), the supplied analyst high, not an independent forecast

Bear Case

  • Limited target headroom: The supplied mean analyst target is effectively level with the current price, while the alternative web extract’s mean is lower.
  • Patent and product pressure: Competition, loss of exclusivity and changing treatment standards can weaken sales in important product lines.
  • Valuation and legal exposure: The 43.32 trailing P/E leaves the share price sensitive to disappointing earnings, while ongoing litigation remains a risk whose latest financial impact isn't quantified in the supplied data.

Bear Target: $260 (-9.0%), the supplied analyst low, not an independent forecast

Risks to Consider

  • Valuation Risk: The trailing P/E is 43.32 and the stock is near its 52-week high. If earnings expectations fall or growth disappoints, the multiple could contract. Forward multiples depend on estimates that may change.
  • Competitive Risk: Medicines face competition from established companies, new therapies and biosimilars. Medical technology products also compete on clinical outcomes, pricing and adoption.
  • Macro Risk: Interest rates, healthcare spending, pricing policy, currency movements and broader economic conditions can affect demand, costs and the value assigned to long-duration earnings.
  • Execution Risk: Research failures, slower launches, manufacturing issues or difficulty replacing revenue from aging products could constrain growth. Litigation and regulatory outcomes can also affect costs and reputation.

Bottom Line

Investment Verdict: NEUTRAL

J&J’s scale, recent earnings beat, cash generation and relatively low beta are constructive features, while its high trailing multiple and proximity to the 52-week high argue for careful attention to expectations. The analyst consensus is favorable, but target estimates place the share price near or above the average target, and the available data do not resolve legal, patent or earnings-growth uncertainties. This report is informational analysis, not investment advice or a recommendation to buy, sell or hold any security.

Action Items for Investors

  • Long-term investors: Track revenue and earnings by business area, product concentration, pipeline progress and dividend coverage over multiple reporting periods. The supplied data don't establish a personal suitability assessment.
  • Short-term traders: Monitor the $288.11 52-week high, the January earnings date and any material company-specific announcements. The price references above are analytical levels, not trade instructions.
  • Risk management: Compare the trailing and forward valuation assumptions, review the differing analyst target datasets and account for litigation, patent and market risks when evaluating exposure.

What to Watch This Week

  • Whether the share price holds near the $280 to $288 area when US trading resumes Monday, November 16.
  • Any company-specific updates on products, legal matters or management outlook; the supplied November 13 news headlines are general dividend coverage.
  • Changes to analyst estimates and targets, noting that the supplied consensus data and web extract do not fully match.

Share this report

Share this article

Spread the word on social media

Think JNJ will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.